Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | SI | P14410 | 1/20 | 0.34 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7595924 | 0.90 | GAA (0.39) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL16157239 | 0.87 | GAA (0.36) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL5156414 | 0.86 | GAA (0.35) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL5160031 | 0.86 | GAA (0.35) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL2169713 | 0.86 | GAA (0.35) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL5156408 | 0.86 | GAA (0.35) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL2169715 | 0.86 | GAA (0.35) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL17525909 | 0.85 | CYP4F2 (0.35) | TSHR | |
| SCHEMBL28485140 | 0.84 | MGAM (0.34) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL15653581 | 0.84 | MGAM (0.34) | MGAMGAASIMGAM2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9315486-B2 | Therapeutic cyclopentanols, compositions thereof, and methods for use thereof | ALLERGAN, INC. (US) | 2016-04-19 | — | — | US | disclosed |
| US-20150119454-A1 | THERAPEUTIC CYCLOPENTANOLS, COMPOSITIONS THEREOF, AND METHODS FOR USE THEREOF | ALLERGAN, INC. | 2015-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119454-A1 | THERAPEUTIC CYCLOPENTANOLS, COMPOSITIONS THEREOF, AND METHODS FOR USE THEREOF | PTGIS, PDE3A, PTGIR | MGAM 3892/4885GAA 2346/4885SI 4265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.